Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
The Schmooze

Diabetic Israeli Children Test Artificial Pancreas

An artificial pancreas was taken for a test drive recently in Israel. This new technology, if it proves successful, could be a huge breakthrough in diabetes care and control.

“A Sweet Life,” a website for healthy living with diabetes, reported that 18 children in Israel were gathered at Kibbutz Ma’aleh Hahamisha to participate in the world’s first out-of-hospital artificial pancreas trial. The study was led by two doctors from the Schneider Children’s Medical Center of Israel: Prof. Moshe Phillip of the Institute of Endocrinology and Diabetes, and and Eran Atlas of the Diabetes Technology Institute.

The kids were testing out Schneider’s MD-Logic system, which allows real-time control of blood glucose levels based on readings from a continuous glucose sensor. While insulin pumps and continuous glucose monitors (both of which are worn attached to the body via cannulas) have made things much easier in recent years for diabetics, there is still a need for the diabetic him or herself (or for a caregiver in the case of a young child or incapacitated senior) to do blood-sugar testing and figure out insulin dosing based on the information provided by the two devices.

MD-Logic, essentially a laptop computer that the kids carried around in a backpack or left on a nightstand when they were asleep, was like a brain that connected the two devices and did all the work for them. Neither they nor their caregivers needed to calculate or manually direct the pumps to deliver the correct amount of insulin.

At least that was how it was supposed to work if the trial ran perfectly. The children were observed and their data monitored at every moment during the day and night, allowing for manual intervention to correct any glitches. According to “A Sweet Life,” the artificial pancreas is not quite ready for prime time, but once it is, it will allow diabetics to get as close as possible to having a functioning pancreas.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse..

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.